FDA Approves New Drug for CLL in Patients with Specific Chromosomal Abnormality
Tuesday, April 12, 2016
FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality.
Approved Venclexta (Venetoclax) for treating patients with chronic lymphocytic leukemia who have chromosomal abnormality called 17P deletion.
Granted Venclexta application breakthrough therapy designation, accelerated approval for patients with CLL who have chromosomal abnormality.
Source : reuters.com
